Yap TA - Search Results

1

Targeting the PI3K pathway in cancer: are we making headway?

Janku F, Yap TA, Meric-Bernstam F. Janku F, et al. Among authors: yap ta. Nat Rev Clin Oncol. 2018 May;15(5):273-291. doi: 10.1038/nrclinonc.2018.28. Epub 2018 Mar 6. Nat Rev Clin Oncol. 2018. PMID: 29508857 Review.

2

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):393-412. doi: 10.1016/j.coph.2008.08.004. Epub 2008 Aug 27. Curr Opin Pharmacol. 2008. PMID: 18721898 Review.

3

Targeting the PI3K/AKT pathway for the treatment of prostate cancer.

Sarker D, Reid AH, Yap TA, de Bono JS. Sarker D, et al. Among authors: yap ta. Clin Cancer Res. 2009 Aug 1;15(15):4799-805. doi: 10.1158/1078-0432.CCR-08-0125. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638457 Free article. Review.

4

Development of therapeutic combinations targeting major cancer signaling pathways.

Yap TA, Omlin A, de Bono JS. Yap TA, et al. J Clin Oncol. 2013 Apr 20;31(12):1592-605. doi: 10.1200/JCO.2011.37.6418. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509311 Review.

5

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U. Rafii S, et al. Among authors: yap ta. Clin Cancer Res. 2015 Apr 15;21(8):1869-76. doi: 10.1158/1078-0432.CCR-14-2424. Epub 2015 Feb 3. Clin Cancer Res. 2015. PMID: 25649020 Free PMC article.

6

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.

Puglisi M, Stewart A, Thavasu P, Frow M, Carreira S, Minchom A, Punwani R, Bhosle J, Popat S, Ratoff J, de Bono J, Yap TA, O''Brien M, Banerji U. Puglisi M, et al. Among authors: yap ta. Oncology. 2016;90(5):280-8. doi: 10.1159/000444928. Epub 2016 Apr 16. Oncology. 2016. PMID: 27082424

7

Circulating tumor DNA-From bench to bedside.

Lim JSJ, Janku F, Yap TA. Lim JSJ, et al. Among authors: yap ta. Curr Probl Cancer. 2017 May-Jun;41(3):212-221. doi: 10.1016/j.currproblcancer.2017.02.005. Epub 2017 Mar 1. Curr Probl Cancer. 2017. PMID: 28416241

8

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

Sundar R, Hong DS, Kopetz S, Yap TA. Sundar R, et al. Among authors: yap ta. Cancer Discov. 2017 Jun;7(6):558-560. doi: 10.1158/2159-8290.CD-17-0087. Cancer Discov. 2017. PMID: 28576843 Free PMC article.

9

Novel insights into mesothelioma biology and implications for therapy.

Yap TA, Aerts JG, Popat S, Fennell DA. Yap TA, et al. Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Nat Rev Cancer. 2017. PMID: 28740119 Review.

10

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. Evans KW, et al. Among authors: yap ta. Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615. Clin Cancer Res. 2017. PMID: 29093017 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page